Decoy Therapeutics (NASDAQ:DCOY) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH assumed coverage on shares of Decoy Therapeutics (NASDAQ:DCOY) in a report released on Friday, MarketBeat reports. The firm issued a buy rating and a $2.50 price objective on the stock.

Decoy Therapeutics Stock Performance

NASDAQ DCOY opened at $0.78 on Friday. The firm has a market capitalization of $4.98 million, a PE ratio of -0.02 and a beta of 0.33. Decoy Therapeutics has a 12 month low of $0.51 and a 12 month high of $43.50.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.